Medical News Today
Potentia Pharmaceuticals, Inc. announced today that it is entering the clinical phase of development for POT-4, its lead drug candidate for the treatment of age-related macular degeneration (AMD). POT-4 is a complement inhibitor, which shuts down the complement activation system that could lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF).